Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
Dis Markers. 2022 May 30;2022:6799898. doi: 10.1155/2022/6799898. eCollection 2022.
Sleep disturbances and benzodiazepine (BZD)/Z-drug use are common in patients with bipolar disorder (BD).
To investigate the short- and long-term effects of BZD/Z-drug use during acute affective episode.
Participants diagnosed with BD as well as sleep disturbance chose BZDs/Z-drugs or not at will. Manic and depressive symptoms were assessed by Mental Disorders Questionnaire (MDQ) and Quick Inventory of Depressive Symptoms (QIDS) as self-reporting surveys. The participants were assessed by trained evaluators at baseline and months 1, 3, 6, and 9.
61 patients with BD combined sleep disturbances were studied. At baseline, patients who used BZDs/Z-drugs had more amount of mood stabilizers ( = 0.038), other psychotropic medications ( = 0.040), and more risk of suicide attempt ( = 0.019). The BZD/Z-drug group had a significantly higher QIDS reductive ratio as compared with the no BZD/Z-drug group at month 1; no significant differences in the variability of MDQ, QIDS reductive ratio, or recurrence rate were found between these two groups at baseline, month 1, month 3, month 6, or month 9.
During acute affective episode, patients with BD combined sleep disturbance who took BZDs/Z-drugs tended to use more amount of mood stabilizers. Polytherapy of BZDs/Z-drugs or other psychiatric drugs could increase suicide attempt during an acute affective episode. BZD/Z-drug use, however, had a significant effect on helping depressive symptoms alleviate during affective period.
睡眠障碍和苯二氮䓬类药物(BZD)/Z 类药物的使用在双相情感障碍(BD)患者中很常见。
研究急性情感发作期间使用 BZD/Z 类药物的短期和长期影响。
被诊断为 BD 且伴有睡眠障碍的患者可自行选择使用 BZDs/Z 类药物或不使用。通过心理障碍问卷(MDQ)和抑郁症状快速清单(QIDS)作为自我报告调查评估躁狂和抑郁症状。参与者在基线和第 1、3、6 和 9 个月时由经过培训的评估人员进行评估。
共研究了 61 例伴有睡眠障碍的 BD 患者。在基线时,使用 BZDs/Z 类药物的患者使用了更多的心境稳定剂(=0.038)、其他精神药物(=0.040),并且自杀未遂的风险更高(=0.019)。与未使用 BZD/Z 类药物的患者相比,BZD/Z 类药物组在第 1 个月时 QIDS 缓解率显著更高;在基线、第 1 个月、第 3 个月、第 6 个月或第 9 个月时,两组之间 MDQ 的变化、QIDS 缓解率或复发率均无显著差异。
在急性情感发作期间,伴有睡眠障碍的 BD 患者在使用 BZDs/Z 类药物时往往会使用更多的心境稳定剂。BZD/Z 类药物或其他精神药物的联合治疗可能会增加急性情感发作期间的自杀未遂风险。然而,BZD/Z 类药物的使用对缓解情感期的抑郁症状有显著影响。